<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of persistent hyperglycemia in type 2 diabetes mellitus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of persistent hyperglycemia in type 2 diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of persistent hyperglycemia in type 2 diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah J Wexler, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Initial treatment of patients with type 2 diabetes mellitus includes lifestyle changes focusing on diet, increased physical activity and exercise, and weight reduction, reinforced by consultation with a registered dietitian and diabetes self-management education, when possible. Monotherapy with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> is indicated for most patients, and insulin may be indicated as initial treatment for those who present with catabolic features (polyuria, polydipsia, weight loss in the setting of very high glucose levels, eg, glycated hemoglobin [A1C] &gt;9 percent) [<a href="#rid1">1</a>]. The natural history of most patients with type 2 diabetes is for blood glucose concentrations to rise gradually with time, and rising glycemia is usually the indication for therapy intensification.</p><p>Treatments for hyperglycemia that fails to respond to initial monotherapy or long-term medication use in type 2 diabetes are reviewed here. Options for initial therapy and other therapeutic issues in diabetes management, such as the frequency of monitoring and evaluation for microvascular and macrovascular complications, are discussed separately. (See  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus"</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120323 utd-content-120430 utd-content-129531">(Related Pathway(s):  <a class="utd-content-120323" href="/pathway/120323?topicRef=1790&amp;source=see_link">Diabetes: Initiation and titration of insulin therapy in non-pregnant adults with type 2 DM</a> and  <a class="utd-content-120430" href="/pathway/120430?topicRef=1790&amp;source=see_link">Diabetes: Initial therapy for non-pregnant adults with type 2 DM</a> and  <a class="utd-content-129531" href="/pathway/129531?topicRef=1790&amp;source=see_link">Diabetes: Medication selection for non-pregnant adults with type 2 DM and persistent hyperglycemia despite monotherapy</a>.)</span></p><p class="headingAnchor" id="H2"><span class="h1">INDICATIONS FOR A SECOND AGENT</span><span class="headingEndMark"> — </span>For most patients, we add a second medication when the individualized glycemic treatment goal is not achieved within three months with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> plus lifestyle intervention. This is consistent with guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) consensus guideline for medical management of hyperglycemia and underscores the importance of avoiding delay in treatment intensification  (<a class="graphic graphic_figure graphicRef111617" href="/d/graphic/111617.html" rel="external">figure 1</a>) [<a href="#rid1">1,2</a>].</p><p>In some patients, early combination therapy is warranted for the kidney or heart protective benefit imparted by selected classes of glucose-lowering medications. (See <a class="local">'Established cardiovascular or kidney disease'</a> below and  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Patient selection'</a> and  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Patient selection'</a>.)</p><p class="headingAnchor" id="H575169615"><span class="h2">Glycemic goals</span><span class="headingEndMark"> — </span>Target A1C goals in patients with type 2 diabetes should be tailored to the individual, balancing the prospect of reduced microvascular complications with the adverse effects and cost of added treatments. Most younger patients without established complications should have an A1C goal of &lt;7 percent (53 mmol/mol) (<a class="calc calc_professional" href="/d/html/15628.html" rel="external">calculator 1</a>), if this can be achieved without significant hypoglycemia, other side effects, or excessive medication burden (due to complexity or cost that may limit adherence). Older adults and those with comorbid conditions or limited life expectancy may have A1C targets up to 8 percent (64 mmol/mol), 8.5 percent (69 mmol/mol), or even higher due to limited likelihood of benefit from intensive therapy balanced against the side effects of medications [<a href="#rid3">3</a>]. Glycemic targets are reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus", section on 'Choosing a glycemic target'</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-129531">(Related Pathway(s):  <a class="utd-content-129531" href="/pathway/129531?topicRef=1790&amp;source=see_link">Diabetes: Medication selection for non-pregnant adults with type 2 DM and persistent hyperglycemia despite monotherapy</a>.)</span></p><p>In order to achieve an A1C goal &lt;7 percent, the following glucose goals are conventionally proposed, but slightly higher levels usually suffice [<a href="#rid4">4,5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fasting glucose 80 to 130 mg/dL (4.4 to 7.2 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Postprandial glucose (90 to 120 minutes after a meal) less than 180 mg/dL (10 mmol/L)</p><p></p><p>After a successful initial response to therapy, patients fail to maintain target A1C levels (&lt;7 percent) at a rate of 5 to 10 percent per year  (<a class="graphic graphic_figure graphicRef81706" href="/d/graphic/81706.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef139800" href="/d/graphic/139800.html" rel="external">figure 3</a>) [<a href="#rid6">6-8</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>UKPDS</strong> – An analysis from the United Kingdom Prospective Diabetes Study (UKPDS) found that 50 percent of "newly diagnosed" patients, identified clinically and originally managed with a single drug, required the addition of a second drug after three years; by nine years, 75 percent of patients needed additional medications to achieve the target fasting plasma glucose level &lt;108 mg/dL (6 mmol/L) and a mean A1C value of 7 percent [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GRADE</strong> – In the GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness) trial, which compared the efficacy and longevity of four different medications (U-100 glargine, <a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a>, <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a>, <a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">sitagliptin</a>) added to <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, 71 percent of participants had primary metabolic failure of the randomly assigned treatment (defined as an A1C ≥7 percent) over a mean follow-up of five years [<a href="#rid10">10</a>]. (See <a class="local">'Without established cardiovascular or kidney disease'</a> below.)</p><p></p><p class="headingAnchor" id="H3196250153"><span class="h2">Causes of rising glycemia</span><span class="headingEndMark"> — </span>Among the factors that can contribute to worsening glycemia are: </p><p class="bulletIndent1"><span class="glyph">●</span>Decreased compliance with diet, exercise, or the medical regimen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weight gain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intercurrent illness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of medicines that can increase insulin resistance, interfere with insulin release, or increase hepatic glucose production, particularly glucocorticoids, atypical antipsychotics, and immunosuppressants  (<a class="graphic graphic_table graphicRef67257" href="/d/graphic/67257.html" rel="external">table 1</a>) [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progression of the underlying diabetes disease process, including decreased insulin secretion and increased insulin resistance (eg, due to weight gain).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Undiagnosed type 1 diabetes with gradual destruction of the pancreatic beta cells, sometimes referred to as "latent autoimmune diabetes in adults" (LADA). (See  <a class="medical medical_review" href="/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes", section on 'Latent autoimmune diabetes in adults (LADA)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient's health care team may not have made appropriate changes in therapy often enough or at all ("therapeutic inertia") [<a href="#rid12">12-15</a>]. A population-based study of over 7200 patients with type 2 diabetes demonstrated that many patients have A1C levels higher than ideal for years owing to a delay in (or absence of) medication changes to improve glycemic management [<a href="#rid12">12</a>]. Adherence to algorithms that dictate changes in treatment at designated intervals and computerized decision aids may improve A1C more efficiently than standard care [<a href="#rid14">14,16,17</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>The therapeutic options for patients who have deterioration of glycemic management on initial therapy with lifestyle intervention and <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> are to add a second oral or injectable agent, including addition of insulin as an option, or to switch to insulin  (<a class="graphic graphic_table graphicRef56876" href="/d/graphic/56876.html" rel="external">table 2</a>).</p><p>Our approach outlined below is largely consistent with American and European guidelines [<a href="#rid1">1,2,18</a>]. The guidelines emphasize the importance of individualizing the choice of medications for the treatment of diabetes, considering important comorbidities (including cardiovascular disease [CVD], heart failure (HF), diabetic kidney disease (DKD), hypoglycemia risk, and need for weight loss) and patient-specific factors (including patient preferences, needs, values, and cost). We also agree with the World Health Organization (WHO) guidelines that sulfonylureas have a long-term safety profile, are inexpensive, and are highly effective, especially when used as described below, with patient education and dose adjustment to minimize side effects [<a href="#rid19">19</a>]. Short-acting sulfonylureas are preferred to reduce the risk of hypoglycemia. <span class="utd-adt-cnt utd-adt-pathwys utd-content-129531">(Related Pathway(s):  <a class="utd-content-129531" href="/pathway/129531?topicRef=1790&amp;source=see_link">Diabetes: Medication selection for non-pregnant adults with type 2 DM and persistent hyperglycemia despite monotherapy</a>.)</span></p><p>Our selection of drugs described below is based upon clinical trial evidence and clinical experience in achieving glycemic targets, with the recognition that there are few high-quality, longer-term, head-to-head drug comparison trials, particularly trials examining clinically important health outcomes (cardiovascular events, mortality) in patients without existing or multiple risk factors for atherosclerotic CVD (ASCVD). (See <a class="local">'Without established cardiovascular or kidney disease'</a> below.)</p><p>In a network meta-analysis of 296 trials evaluating the effects of selected metformin-based combinations on A1C, mortality, and vascular outcomes in a heterogeneous group of patients with variable cardiovascular risk, the greatest reduction in A1C was seen with the addition of glucagon-like peptide 1 (GLP-1) receptor agonists, premixed insulin, basal-bolus insulin, basal insulin, or prandial insulin (reductions in A1C ranging from -0.67 for prandial insulin to -1.33 percentage points for subcutaneous <a class="drug drug_general" data-topicid="115980" href="/d/drug information/115980.html" rel="external">semaglutide</a>) [<a href="#rid20">20</a>]. For patients at low cardiovascular risk, all treatments were similar to placebo for vascular outcomes. For patients at increased cardiovascular risk, oral semaglutide, <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, and <a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a> (all compared with placebo) reduced all-cause mortality and cardiovascular death (odds ratios [ORs] ranging from 0.5 to 0.87). Sodium-glucose co-transporter 2 (SGLT2) inhibitors, in general, had favorable effects on hospitalization for HF and progression of renal disease.</p><p>In other meta-analyses, <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> combination therapy decreased A1C levels more than metformin monotherapy by approximately 1 percentage point [<a href="#rid21">21,22</a>]. Most combinations similarly reduced A1C. Moderate evidence favored metformin plus a GLP-1 receptor agonist over metformin plus a dipeptidyl peptidase 4 (DPP-4) inhibitor for reducing A1C levels [<a href="#rid21">21</a>]. As expected, the use of thiazolidinediones, sulfonylureas, and insulin was associated with weight gain, while metformin, GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors were associated with weight loss or weight maintenance. Sulfonylureas were associated with higher rates of hypoglycemia.</p><p>Combination tablets of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> and all of the oral agents are available in several doses. For patients who are doing well on these particular doses, the combination tablets offer the convenience of taking fewer pills. However, if the patient requires that the dose of either drug be changed independent of the other drug, then a fixed combination is unhelpful. In addition, the cost of the brand name combinations is substantially greater than the generic components individually. </p><p class="headingAnchor" id="H7554285"><span class="h2">Monotherapy failure</span><span class="headingEndMark"> — </span>For patients with deterioration of glycemic management while taking initial oral monotherapy, many available medication classes can be used with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> or in combination with each other if metformin is contraindicated or not tolerated. <span class="utd-adt-cnt utd-adt-pathwys utd-content-129531 utd-content-120323">(Related Pathway(s):  <a class="utd-content-129531" href="/pathway/129531?topicRef=1790&amp;source=see_link">Diabetes: Medication selection for non-pregnant adults with type 2 DM and persistent hyperglycemia despite monotherapy</a> and  <a class="utd-content-120323" href="/pathway/120323?topicRef=1790&amp;source=see_link">Diabetes: Initiation and titration of insulin therapy in non-pregnant adults with type 2 DM</a>.)</span></p><p>Since <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> has an excellent safety profile, is generally well tolerated, helps stabilize weight, reduces the required dose of the second medication, and is inexpensive, we continue it and add other medications as needed  (<a class="graphic graphic_figure graphicRef111617" href="/d/graphic/111617.html" rel="external">figure 1</a>). For patients who develop contraindications or intolerance to metformin, we replace metformin with other medications [<a href="#rid1">1,2</a>]. All glucose-lowering medications have advantages and disadvantages, with widely varying side-effect profiles  (<a class="graphic graphic_table graphicRef56876" href="/d/graphic/56876.html" rel="external">table 2</a>). All of the newer medicines that are not available in generic form are relatively expensive.</p><p>For patients with persistent hyperglycemia while taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> (2000 mg per day or a lower maximally tolerated dose), the choice of a second medication should be individualized based on efficacy, risk for hypoglycemia, the patient's comorbid conditions, impact on weight, side effects, and cost.</p><p class="headingAnchor" id="H296655651"><span class="h3">A1C &gt;9 percent (74.9 mmol/mol) or persistent symptoms of hyperglycemia</span><span class="headingEndMark"> — </span>In this circumstance, insulin, a GLP-1 receptor agonist, or a dual-acting GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist are the suggested second-line medications, as they have been shown to have the best glycemic efficacy  (<a class="graphic graphic_algorithm graphicRef135209" href="/d/graphic/135209.html" rel="external">algorithm 1</a>) [<a href="#rid20">20</a>]. We do not typically use an SGLT2 inhibitor in this setting due to inferior glycemic efficacy [<a href="#rid23">23,24</a>] and the potential for increasing symptoms from polyuria.</p><p>Insulin is always effective and is preferred in insulin-deficient, catabolic diabetes (eg, polyuria, polydipsia, weight loss) (see <a class="local">'Insulin initiation and intensification'</a> below). While basal insulin has historically been the preferred medication to add to <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> when A1C is markedly elevated (even in the absence of catabolic symptoms), GLP-1 receptor agonists are an effective alternative to basal insulin when type 1 diabetes is not likely. However, no long-term studies have compared insulin and GLP-1 receptor agonists when the starting A1C is very high (eg, &gt;9 percent), so in this setting we generally prefer initiating insulin therapy. However, for patients with established ASCVD in particular, specific GLP-1 receptor agonists that have demonstrated cardiovascular benefit (<a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a>, <a class="drug drug_general" data-topicid="115980" href="/d/drug information/115980.html" rel="external">semaglutide</a>, or <a class="drug drug_general" data-topicid="97148" href="/d/drug information/97148.html" rel="external">dulaglutide</a>) may be preferred, provided they achieve the desired glycemic target. Gastrointestinal (GI) side effects and contraindications to GLP-1 receptor agonists, as well as cost, may limit their use. (See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Adverse effects'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insulin</strong> – While neutral protamine Hagedorn (NPH) insulin has been used commonly at bedtime to supplement oral hypoglycemic drug therapy, longer-acting insulin analogs, such as <a class="drug drug_general" data-topicid="9023" href="/d/drug information/9023.html" rel="external">insulin glargine</a> (once daily), detemir (once or twice daily), and degludec (once daily), added to oral agents are similarly effective for reducing A1C values and may cause marginally less nocturnal hypoglycemia depending on dosing and glycemic targets. However, longer-acting analogs are similar to NPH with regard to total or severe hypoglycemia and have the important disadvantage of higher cost. These data are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus", section on 'Choice of basal insulin'</a>.)</p><p></p><p class="bulletIndent1">Part of the rationale for combination <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> and insulin therapy is that the patient can retain the convenience of oral agents and potential weight benefit of metformin while minimizing total insulin dose requirements and, therefore, the degree of hyperinsulinemia [<a href="#rid25">25</a>]. There are few trials, however, evaluating clinically important outcomes, such as cardiovascular or all-cause mortality, with combined metformin and insulin [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">In several trials and a meta-analysis, glycemic management was equivalent or improved with metformin-insulin combinations compared with insulin monotherapy or with sulfonylurea-insulin combinations, with lower insulin doses and less weight gain  (<a class="graphic graphic_figure graphicRef80026" href="/d/graphic/80026.html" rel="external">figure 4</a>) [<a href="#rid26">26-29</a>]. In the United Kingdom Prospective Diabetes Study (UKPDS), the combination of insulin with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> was also associated with significantly less weight gain than twice-daily insulin injections or insulin combined with sulfonylureas [<a href="#rid30">30</a>]. This is consistent with other observations that metformin alone does not usually produce weight gain [<a href="#rid7">7</a>]. Combining insulin and sulfonylurea is usually not endorsed, as they have similar mechanisms of action (providing more insulin), and the same glucose-lowering effect can usually be achieved with a modestly higher dose of insulin alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GLP-1 receptor agonists</strong> – Data supporting the selection of subcutaneous injection GLP-1 receptor agonists versus basal insulin (as add-on therapy to <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>) at this glycemic threshold are limited by the fact that most studies have neither performed this direct comparison nor exclusively enrolled patients with a high A1C. In addition, in some trials, insulin was often not adjusted as indicated based on labeling and usual clinical practice [<a href="#rid31">31,32</a>]. With those caveats, subcutaneous injection GLP-1 receptor agonists may be as effective as basal insulin in patients with initially high A1C levels [<a href="#rid33">33,34</a>].</p><p></p><p class="bulletIndent1">GLP-1 receptor agonists have been compared with basal insulin in combination with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, often as a third agent added to metformin and another oral glucose-lowering medication. In most of these trials, GLP-1 receptor agonists have achieved at least equivalent glycemic management as the addition of basal insulin with the added benefit of weight loss, rather than weight gain, as is often seen with basal insulin. In a 26-week trial that enrolled patients with A1C values as high as 11 percent (mean A1C 8.3 percent), the reduction in A1C was greater with <a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a> (-1.33 versus -1.09 percentage points with glargine), with weight loss of 1.8 kg in the liraglutide arm and weight increase of 1.6 kg in the glargine arm [<a href="#rid31">31</a>]. These trials are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dual-acting GLP-1 and GIP receptor agonist</strong> –<strong> </strong><a class="drug drug_general" data-topicid="138675" href="/d/drug information/138675.html" rel="external">Tirzepatide</a> is a dual-acting GLP-1 and GIP receptor agonist with high glucose-lowering efficacy. In a 40-week trial that compared tirzepatide with <a class="drug drug_general" data-topicid="115980" href="/d/drug information/115980.html" rel="external">semaglutide</a> in 1878 participants with type 2 diabetes, tirzepatide conferred greater reduction in A1C and body weight [<a href="#rid35">35</a>]. Clinical data are not yet available to establish whether tirzepatide also provides the cardiovascular or kidney protective benefits shown for some GLP-1 receptor agonists. Trial data demonstrating the glycemic and weight loss efficacy of tirzepatide are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Clinical outcomes'</a>.)</p><p></p><p class="headingAnchor" id="H4038294578"><span class="h3">A1C ≤9 percent</span><span class="headingEndMark"> — </span>To select a second medication, we use shared decision-making with a focus on beneficial and adverse effects within the context of the degree of hyperglycemia as well as a patient's comorbidities and preferences. Data from small trials demonstrate substantial inter-individual variability in treatment response to specific medications for endpoints including glycemia and reduction in albuminuria [<a href="#rid36">36,37</a>], further underscoring the importance of individualized therapy.</p><p class="headingAnchor" id="H789018119"><span class="h4">Established cardiovascular or kidney disease</span><span class="headingEndMark"> — </span>For patients with existing ASCVD, HF, or albuminuric DKD, a glucose-lowering medication with evidence of cardiac or kidney benefit should be added to <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>  (<a class="graphic graphic_algorithm graphicRef135210" data-inline-graphics="135210" href="/d/graphic/135210.html" rel="external">algorithm 2</a>).</p><p>As examples: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>ASCVD</strong> – For patients in whom ASCVD<strong> </strong>is the predominant comorbidity, particularly in the setting of<strong> </strong>higher A1C or motivation to lose weight, we typically prefer <a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a>, subcutaneous <a class="drug drug_general" data-topicid="115980" href="/d/drug information/115980.html" rel="external">semaglutide</a>, or <a class="drug drug_general" data-topicid="97148" href="/d/drug information/97148.html" rel="external">dulaglutide</a>. SGLT2 inhibitors with cardiovascular benefit (<a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> or <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>) are good alternatives. (See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HF and/or DKD</strong> – For patients in whom HF or DKD (albuminuria [urine albumin excretion &gt;200 mg/day] and estimated glomerular filtration rate [eGFR] &lt;60 but ≥25 mL/min/1.73 m<sup>2</sup>) is the predominant comorbidity, we prescribe a low dose of an SGLT2 inhibitor (<a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>). In the setting of declining eGFR, the main reason to prescribe an SGLT2 inhibitor is to reduce progression of DKD. For the treatment of hyperglycemia, SGLT2 inhibitors are not recommended for initiation with eGFR &lt;30 to 45 mL/min/1.73 m<sup>2</sup>, with some differences in each medication depending on the labeling. However, cardiac and kidney benefits have been shown in patients with eGFR below this threshold. (See  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease", section on 'Type 2 diabetes: Treat with additional kidney-protective therapy'</a>.)</p><p></p><p>In the absence of randomized trials directly comparing cardiovascular outcomes of the GLP-1 receptor agonists and SGLT2 inhibitors, the following findings and those from network meta-analyses [<a href="#rid38">38,39</a>] largely support our approach outlined above:</p><p class="bulletIndent1"><span class="glyph">●</span>When compared with placebo, the GLP-1 receptor agonists <a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a>, subcutaneous <a class="drug drug_general" data-topicid="115980" href="/d/drug information/115980.html" rel="external">semaglutide</a>, and <a class="drug drug_general" data-topicid="97148" href="/d/drug information/97148.html" rel="external">dulaglutide</a> demonstrated favorable atherosclerotic cardiovascular and kidney outcomes, including a reduction in cardiovascular and overall mortality [<a href="#rid38">38,40-46</a>]. (See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When compared with placebo, the SGLT2 inhibitors <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, and <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> have also demonstrated benefit for cardiovascular and kidney outcomes, especially for HF hospitalization, risk of kidney disease progression, and cardiovascular and overall mortality [<a href="#rid38">38,45-51</a>]. (See  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Cardiovascular effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The majority of patients in these cardiovascular outcomes trials had established CVD or DKD with severely increased albuminuria, and therefore, these are the primary indications for adding one of these medications. Patients at high CVD risk but without a prior event might benefit, but the data are less definitive [<a href="#rid45">45</a>]. Similarly, patients without severely increased albuminuria derive some benefit, but the absolute benefits are greater among those with severely increased albuminuria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a population-based cohort study (over 370,000 patients with type 2 diabetes) evaluating whether SGLT2 inhibitors or GLP-1 receptor agonists added to baseline diabetes therapy are associated with differential CVD benefits, the use of SGLT2 inhibitors compared with GLP-1 receptor agonists was associated with reductions in HF hospitalizations in patients with or without underlying CVD (rate difference for those with history of CVD, -4.97 events per 1000 person-years, 95% CI -6.55 to -3.39) [<a href="#rid52">52</a>]. For the other primary outcome (a composite of hospitalization for myocardial infarction or stroke), there was a small benefit with SGLT2 inhibitors in patients with a history of CVD (rate difference -2.47 events per 1000 person-years, 95% CI -4.45 to -0.50). There was no difference in CVD outcomes between the two classes in those without a history of CVD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite the small ASCVD benefit of SGLT2 inhibitors [<a href="#rid38">38,39,52</a>], the benefit of GLP-1 receptor agonists on stroke observed in the <a class="drug drug_general" data-topicid="115980" href="/d/drug information/115980.html" rel="external">semaglutide</a> [<a href="#rid40">40</a>] and <a class="drug drug_general" data-topicid="97148" href="/d/drug information/97148.html" rel="external">dulaglutide</a> [<a href="#rid43">43</a>] cardiovascular outcomes trials, as well as their efficacy for overall diabetes management, leads many, including us, to favor them over SGLT2 inhibitors in the absence of HF or DKD [<a href="#rid53">53</a>]. </p><p></p><p>Of note, SGLT2 inhibitors have <strong>decreasing glycemic efficacy as eGFR declines</strong>, particularly with eGFR &lt;45 mL/min/1.73 m<sup>2</sup>, and in this setting, an alternative or additional agent may be necessary to achieve glycemic goals. GLP-1 receptor agonists are an alternative since glycemic benefit is independent of kidney function. In addition, GLP-1 receptor agonists have been shown to slow the rate of decline in eGFR and prevent worsening of albuminuria, albeit to a lesser degree than SGLT2 inhibitors. GLP-1 receptor agonists should be titrated slowly, with monitoring for GI side effects, which could precipitate dehydration and acute kidney injury (AKI). (See  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Microvascular outcomes'</a>.)</p><p>We avoid use of SGLT2 inhibitors in patients with frequent genitourinary yeast infections or bacterial urinary tract infections, low bone density and high risk for falls and fractures, foot ulceration, and factors predisposing to diabetic ketoacidosis (eg, pancreatic insufficiency, drug or alcohol use disorder) because of increased risk for each while using these agents. SGLT2 inhibitors should be held for procedures, colonoscopy preparation, and with poor oral intake to prevent diabetic ketoacidosis. (See  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Contraindications and precautions'</a>.)</p><p>The treatment of hyperglycemia in the setting of nondialysis CKD and eGFR &lt;30 mL/min/1.73 m<sup>2</sup> is reviewed separately. In general, we tolerate higher glycemic targets, and, if medication is required, we prefer a short-acting, low-dose sulfonylurea (eg, <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a>), <a class="drug drug_general" data-topicid="9604" href="/d/drug information/9604.html" rel="external">repaglinide</a>, <a class="drug drug_general" data-topicid="16490" href="/d/drug information/16490.html" rel="external">linagliptin</a>, or cautious use of a GLP-1 receptor agonist or insulin. (See  <a class="medical medical_review" href="/d/html/1857.html" rel="external">"Management of hyperglycemia in patients with type 2 diabetes and advanced chronic kidney disease or end-stage kidney disease", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus", section on 'Use in chronic kidney disease'</a> and  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus", section on 'Clinical use of meglitinides'</a>.)</p><p class="headingAnchor" id="H1363021631"><span class="h4">Without established cardiovascular or kidney disease</span><span class="headingEndMark"> — </span>For most patients without established ASCVD or kidney disease who have persistent hyperglycemia while taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> (2000 mg per day or a lower maximally tolerated dose), we suggest a GLP-1 receptor agonist or basal insulin based on the results of the GRADE trial, a comparative effectiveness study of commonly used classes of glucose lowering medications  (<a class="graphic graphic_algorithm graphicRef135210" href="/d/graphic/135210.html" rel="external">algorithm 2</a>) [<a href="#rid10">10,54</a>].</p><p>In the GRADE trial, choice of a second glucose-lowering medication was evaluated in 5047 patients with type 2 diabetes (A1C 6.8 to 8.5 percent [50.8 to 69.4 mmol/mol], mean body mass index [BMI] 34 kg/m<sup>2</sup>) and low baseline prevalence of cardiovascular or kidney disease [<a href="#rid10">10</a>]. Participants with hyperglycemia despite taking maximum tolerated doses of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> were randomly assigned to treatment with U-100 glargine, <a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a>, <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a>, or <a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">sitagliptin</a>. Over a mean follow-up of five years, all four medications lowered A1C levels. The proportion of patients with A1C ≥7 percent was modestly lower with glargine (67.4 percent, hazard ratio [HR] 0.87, 95% CI 0.80-0.94 compared with the other three treatments combined) and liraglutide (68.2 percent, HR 0.84, 95% CI 0.78-0.91) than with glimepiride (72.4 percent, HR 1.01, 95% CI 0.93-1.09) or sitagliptin (77.4 percent, HR 1.37, 95% CI 1.27-1.48). The medications had a parallel effect on the secondary metabolic outcome, with 39 percent of glargine-treated participants exceeding A1C &gt;7.5 percent compared with 46, 50, and 55 percent with liraglutide, glimepiride, and sitagliptin, respectively [<a href="#rid10">10</a>].</p><p>The proportion of individuals with weight gain of ≥10 percent was lowest in the <a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a> group (6.1 versus 13.1, 12.1, and 9.1 percent for glargine, <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a>, and <a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">sitagliptin</a>, respectively) [<a href="#rid10">10</a>]. The proportion of individuals with severe hypoglycemia was highest in the glimepiride group (2.2 versus 1.3, 1, and 0.7 percent for glargine, liraglutide, and sitagliptin, respectively). Liraglutide had the highest frequency of gastrointestinal side effects.</p><p>The treatment groups did not differ in the rate of the prespecified secondary micro- or macrovascular outcomes, including moderately or severely increased albuminuria, reduced kidney function, peripheral neuropathy, major adverse cardiovascular events (MACE), hospitalization for HF, cardiovascular mortality, or overall mortality [<a href="#rid54">54,55</a>]. However, there was a small reduction in the incidence of any CVD (defined as first incidence of MACE, hospitalization for unstable angina or HF, or revascularization in any arterial bed) with <a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a> (6.6 percent) compared with the other medications (9, 9.2, and 9.6 percent for insulin, <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a>, and <a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">sitagliptin</a>, respectively; HR 0.7, 95% CI 0.6-0.9 for liraglutide compared with the other three medications combined). </p><p>The GRADE trial was designed and implemented prior to the availability of SGLT2 inhibitors. SGLT2 inhibitors have lower glycemic efficacy compared with basal insulin and GLP-1 receptor agonists [<a href="#rid20">20</a>]. The cardiovascular benefit of SGLT2 inhibitors has not been demonstrated in those at low cardiovascular risk.</p><p class="bulletIndent1">Shorter-term trial data also support selection of the dual-acting GLP-1 and GIP receptor agonist <a class="drug drug_general" data-topicid="138675" href="/d/drug information/138675.html" rel="external">tirzepatide</a> as a second glucose-lowering agent, particularly in individuals for whom substantial body weight loss is a treatment goal. Trial data for tirzepatide are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Clinical outcomes'</a>.)</p><p></p><p>For patients who are opposed to injection therapy and/or who decline or cannot tolerate GLP-1 receptor agonists or insulin, GRADE demonstrated that other available medications also effectively reduce A1C. The choice of an alternative glucose-lowering medication is guided by efficacy, patient comorbidities, preferences, side effects, and cost  (<a class="graphic graphic_algorithm graphicRef135210" href="/d/graphic/135210.html" rel="external">algorithm 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cost concerns</strong> – In this circumstance, sulfonylureas are reasonable second agents because they are inexpensive, effective, universally available, and have a long-term track record, including demonstration of reduced risk of microvascular complications. These benefits are offset by risks of hypoglycemia and modest weight gain. Sulfonylureas can be used safely and effectively with dose adjustment, even in people at risk of hypoglycemia, but this requires a bit more attention. We prefer a shorter-duration sulfonylurea or one with relatively lower risk for hypoglycemia (eg, <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a>, <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a>), since longer-acting <a class="drug drug_general" data-topicid="8494" href="/d/drug information/8494.html" rel="external">glyburide</a> is associated with a higher risk of hypoglycemia, especially in older or frail patients. In addition, there are good data providing reassurance of the cardiovascular safety of these sulfonylureas. (See  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a>.)</p><p></p><p class="bulletIndent1">The glycemic efficacy of sulfonylureas in combination with other oral agents is illustrated by the findings of a meta-analysis of trials in which sulfonylureas were added to oral agents (predominantly <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> or thiazolidinediones) [<a href="#rid56">56</a>]. Compared with placebo, the addition of sulfonylureas to oral diabetes treatment lowered A1C by 1.62 percentage points. The clinical use, side effects, and concerns about the cardiovascular safety of sulfonylureas are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of hypoglycemia</strong> – For patients in whom avoidance of any hypoglycemia is desirable, GLP-1 receptor agonists, SGLT2 inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, or, much less commonly, <a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">pioglitazone</a> are options as they are associated with a low hypoglycemia risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weight concerns</strong> – When weight loss is a priority, medications that promote weight loss, such as GLP-1 receptor agonists, a dual-acting GLP-1 and GIP receptor agonist (<a class="drug drug_general" data-topicid="138675" href="/d/drug information/138675.html" rel="external">tirzepatide</a>), or SGLT2 inhibitors, or medications that are weight neutral, such as DPP-4 inhibitors, may be selected as a second agent. SGLT2 inhibitors are associated with modest weight loss. With both medication classes, weight loss effects are stronger when the medication is combined with sustained efforts at dietary modification.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NASH</strong> – For patients with nonalcoholic steatohepatitis (NASH), any drug that causes weight loss may be beneficial. In patients with diabetes mellitus and biopsy-proven NASH, <a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">pioglitazone</a> has been shown to improve fibrosis as well as inflammation and steatosis. GLP-1-based therapies also appear to improve liver biopsy evidence of NASH. These studies are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults", section on 'Patients with NASH and diabetes'</a>.)</p><p></p><p class="bulletIndent1">The potential benefits of these drugs must be balanced with their associated adverse effects. In particular, <a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">pioglitazone</a> is not typically a first-choice agent due to adverse effects, including increased risk of weight gain, fluid retention, HF, fractures, and the potential increased risk of bladder cancer. It may play a role in the treatment of selected patients with severe insulin resistance, NASH (or nonalcoholic fatty liver disease), at low risk of fracture. Adverse effects of pioglitazone may be minimized by using 15 to 30 mg rather than the 45 mg (highest) dose. (See  <a class="medical medical_review" href="/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults", section on 'Patients with NASH and diabetes'</a> and  <a class="medical medical_review" href="/d/html/1757.html" rel="external">"Thiazolidinediones in the treatment of type 2 diabetes mellitus", section on 'Safety'</a> and  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Adverse effects'</a>.)</p><p></p><p>Trials comparing other combinations are reviewed separately in the individual topics. (See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Glycemic efficacy'</a> and  <a class="medical medical_review" href="/d/html/96015.html" rel="external">"Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus", section on 'Glycemic efficacy'</a> and  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Glycemic efficacy'</a>.)</p><p class="headingAnchor" id="H7554297"><span class="h2">Dual agent failure</span><span class="headingEndMark"> — </span>For patients who have deterioration of glycemic management on dual therapy, the options include:</p><p class="bulletIndent1"><span class="glyph">●</span>Insulin (starting or intensifying) – May simplify regimen by eliminating sulfonylureas or other relatively weak oral agents, such as DPP-4 inhibitors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two oral agents and a GLP-1 or dual-acting GLP-1 and GIP receptor agonist, but DPP-4 inhibitors and GLP-1/dual-acting receptor agonists should not be combined [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One oral agent (usually <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>), basal insulin, and a GLP-1 receptor agonist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many permutations of three oral agents (eg, <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> and short-acting sulfonylurea plus SGLT2 inhibitor or DPP-4 inhibitor); many other combinations are possible, but, again, DPP-4 inhibitors and GLP-1 receptor agonists should not be combined [<a href="#rid57">57</a>]).</p><p></p><p>Although guidelines suggest combining SGLT2 inhibitors and GLP-1 receptor agonists [<a href="#rid1">1</a>], we do not usually add an SGLT2 inhibitor to GLP-1 receptor agonist therapy for hyperglycemia alone given the absence of data showing additive cardiovascular and kidney benefit and increased patient burden (cost, polypharmacy, adverse effects). However, we do combine the medications if strong indications exist for each class (eg, a patient with type 2 diabetes, obesity, A1C &gt;9 percent, and severely elevated albuminuria).</p><p>The choice of additional therapy should be individualized, as discussed above for patients with monotherapy failure, based on efficacy, glycemic target, risk of hypoglycemia, the patient's underlying comorbidities, impact on weight, side effects, and cost. (See <a class="local">'Monotherapy failure'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>For most patients who do not achieve target A1C with initial combination treatment, we suggest starting or intensifying insulin therapy or starting a GLP-1 receptor agonist (see <a class="local">'Insulin initiation and intensification'</a> below). In patients on sulfonylureas and <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> who are starting insulin therapy, sulfonylureas are generally discontinued, while metformin is continued. In patients on a DPP-4 inhibitor who are starting a GLP-1 receptor agonist or dual-acting GLP-1 and GIP receptor agonist, the DPP-4 inhibitor should be discontinued.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For appropriate patients with cardiovascular and kidney comorbidities, a GLP-1 receptor agonist or an SGLT2 inhibitor should be added to the regimen. Insulin dose requirements can decrease precipitously with the addition of these medications, requiring patient education and close follow-up with insulin dose adjustment in the short term to reduce the risk of hypoglycemia. (See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Cardiovascular effects'</a>.)</p><p></p><p>In a meta-analysis of randomized trials evaluating the addition of a third agent in patients inadequately managed with two agents (predominantly <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> and a sulfonylurea or metformin and a thiazolidinedione), triple-agent combinations reduced A1C to a greater extent than two agents [<a href="#rid58">58</a>]. In trials lasting 52 to 54 weeks, the addition of thiazolidinediones, GLP-1 receptor agonists, or SGLT2 inhibitors to metformin and sulfonylurea reduced A1C to a similar extent, and <a class="drug drug_general" data-topicid="138675" href="/d/drug information/138675.html" rel="external">tirzepatide</a> imparted even greater A1C reduction. However, these trials did not directly compare the third-line agents with each other. Moreover, only the GRADE study was of sufficient duration to determine long-term glycemic effects.</p><p>For patients who are not well managed on two oral agents, switching to insulin may be less expensive than adding a third oral or injectable agent, depending on which insulin and which third oral or injectable agent is selected.</p><p class="headingAnchor" id="H7554623"><span class="h2">Insulin initiation and intensification</span><span class="headingEndMark"> — </span>If a decision has been made to add insulin to oral hypoglycemic therapy in patients with type 2 diabetes, a single daily dose of either <a class="drug drug_general" data-topicid="9028" href="/d/drug information/9028.html" rel="external">insulin NPH</a> or detemir given at bedtime or <a class="drug drug_general" data-topicid="9023" href="/d/drug information/9023.html" rel="external">insulin glargine</a> or degludec given in the morning or at bedtime is a reasonable initial regimen [<a href="#rid1">1</a>]. <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a>, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors can be continued when insulin is added, whereas sulfonylureas and <a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">pioglitazone</a> are usually discontinued due to reduced efficacy in comparison with other combinations and to adverse effects [<a href="#rid59">59</a>]. Patients should measure blood glucose at appropriate times, and usually once to twice per day, depending on the insulin used and timing of administration. For example, if bedtime NPH is used, it should be adjusted based on fasting glucose levels. More frequent self-monitoring should be implemented during insulin dose adjustment and when changes in daily activities (traveling, changes in diet or exercise pattern) or acute illness makes insulin adjustments necessary. The dose of basal or long-acting insulin may be adjusted every three to four days until fasting glucose targets are achieved. Once an insulin regimen is stable, less frequent glucose monitoring may suffice. (See  <a class="medical medical_review" href="/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus", section on 'Titrating dose'</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120323">(Related Pathway(s):  <a class="utd-content-120323" href="/pathway/120323?topicRef=1790&amp;source=see_link">Diabetes: Initiation and titration of insulin therapy in non-pregnant adults with type 2 DM</a>.)</span></p><p>For patients who continue to have poor glycemic management on basal insulin after titration, diet and exercise patterns should be reviewed. Potential next steps include adding rapid-acting insulin before the largest meal and then two or three meals (if needed), adding a GLP-1 receptor agonist, or changing to premixed insulin twice daily  (<a class="graphic graphic_figure graphicRef118049" href="/d/graphic/118049.html" rel="external">figure 5</a>). Several premixed combinations of basal and prandial insulin or basal insulin and a GLP-1 receptor agonist are available. (See  <a class="medical medical_review" href="/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus", section on 'Designing an insulin regimen'</a> and  <a class="medical medical_review" href="/d/html/1752.html" rel="external">"General principles of insulin therapy in diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"</a>.)</p><p>Use of an intensive insulin regimen with multiple daily injections (MDI; similar to that used in type 1 diabetes) may be necessary in insulin-deficient type 2 diabetes. Patients with type 2 diabetes on MDI or with insulin deficiency may benefit from devices used more commonly in type 1 diabetes such as insulin pumps or continuous glucose monitors. (See  <a class="medical medical_review" href="/d/html/123060.html" rel="external">"Continuous subcutaneous insulin infusion (insulin pump)"</a> and  <a class="medical medical_review" href="/d/html/1781.html" rel="external">"Glucose monitoring in the ambulatory management of nonpregnant adults with diabetes mellitus", section on 'CGM systems'</a>.)</p><p>MDI results in higher serum insulin concentrations and better glycemic management than that achieved with either an oral drug or basal insulin therapy alone [<a href="#rid7">7</a>]. MDI in type 2 diabetes may require large doses of insulin to overcome insulin resistance and can be associated with substantial weight gain (averaging 8.7 kg in one study) [<a href="#rid25">25</a>]. Patients with type 2 diabetes with generalized obesity or with central overweight, often with nonalcoholic fatty liver disease, frequently require insulin doses in the range of 65 to 100 units per day or much higher. Although the total daily dose of insulin may be high, the insulin dose per kilogram is less remarkable. High daily insulin requirements may prompt consideration of use of concentrated insulins, such as U-300 glargine or U-500 <a class="drug drug_general" data-topicid="9030" href="/d/drug information/9030.html" rel="external">regular insulin</a>. Concentrated insulin formulations deliver more potent insulins in smaller volumes, which is less cumbersome for patients and facilitates improved insulin absorption. (See  <a class="medical medical_review" href="/d/html/1752.html" rel="external">"General principles of insulin therapy in diabetes mellitus", section on 'U-500 regular insulin'</a> and  <a class="medical medical_review" href="/d/html/1752.html" rel="external">"General principles of insulin therapy in diabetes mellitus", section on 'Basal insulin analogs'</a>.)</p><p>While use of concentrated insulins is often effective for glycemic management, the worsening obesity associated with high-dose insulin can result in progressively increasing insulin requirements. This phenomenon may then lead to reconsideration of addition of an insulin-sparing agent (eg, GLP-1 receptor agonist or thiazolidinedione) or bariatric surgery. (See <a class="local">'Bariatric (metabolic) surgery'</a> below and  <a class="medical medical_review" href="/d/html/1766.html" rel="external">"Nutritional considerations in type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H7556192"><span class="h1">CARDIOVASCULAR AND OTHER OUTCOMES</span><span class="headingEndMark"> — </span>In the decade following new US Food and Drug Administration (FDA) guidance released in 2008, approved diabetes drugs were required to be evaluated for cardiovascular disease (CVD) safety with large trials. The vast majority of these CVD safety studies were placebo-controlled and enrolled all or a majority of patients with pre-existing CVD or at high cardiovascular risk, representing a minority of the type 2 diabetes population. The long-term benefits and risks of using one agent over another in the <strong>absence </strong>of diagnosed CVD or high atherosclerotic CVD (ASCVD) risk are less clear. Thus, the results of these trials are most applicable to patients similar to the trial population and not to all patients with type 2 diabetes [<a href="#rid2">2,60</a>]. Cardiovascular benefit has been demonstrated for some of these medications when taken in combination with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, but benefit has not been definitively established in drug-naïve patients at low to moderate cardiovascular risk. (See <a class="local">'Without established cardiovascular or kidney disease'</a> above.)</p><p>The cardiovascular effects of each diabetes drug (when data are available) is reviewed in the individual topics. (See  <a class="medical medical_review" href="/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/1757.html" rel="external">"Thiazolidinediones in the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/96015.html" rel="external">"Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">MEDICATIONS NOT USUALLY RECOMMENDED</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha-glucosidase inhibitors</strong> – <a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">Acarbose</a> and <a class="drug drug_general" data-topicid="9538" href="/d/drug information/9538.html" rel="external">miglitol</a> are not preferred second- or third-line medications, because of generally poor tolerance due to gastrointestinal side effects that do not lessen over time [<a href="#rid2">2,61</a>]. They can reduce A1C values slightly (0.5 to 1 percentage points) when taken in conjunction with any other form of therapy [<a href="#rid62">62,63</a>]. They act predominantly by lowering glucose concentrations after meals but may be poorly tolerated because of flatulence and other gastrointestinal (GI) side effects. However, if they are started at a low dose (25 mg before meals) and slowly increased, they can be effective in people who follow high-carbohydrate diets. (See  <a class="medical medical_review" href="/d/html/1787.html" rel="external">"Alpha-glucosidase inhibitors for treatment of diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pramlintide</strong> – <a class="drug drug_general" data-topicid="10327" href="/d/drug information/10327.html" rel="external">Pramlintide</a> is a synthetic analog of human amylin that slows gastric emptying, reduces postprandial rises in blood glucose concentrations, and modestly improves A1C concentrations in patients with type 1 and type 2 diabetes when injected subcutaneously three times per day. Pramlintide is only approved for use in patients also taking prandial insulin, and therefore, it is not generally used in patients with type 2 diabetes. It also has frequent GI side effects. (See  <a class="medical medical_review" href="/d/html/1758.html" rel="external">"Amylin analogs for the treatment of diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled insulin</strong> – An inhaled form of rapid-acting insulin was approved and available for a short time but was discontinued in 2007 for commercial reasons. In 2014, another <a class="drug drug_general" data-topicid="99568" href="/d/drug information/99568.html" rel="external">inhaled insulin</a> preparation was approved by the US Food and Drug Administration (FDA). Inhaled insulin causes a very rapid rise in serum insulin concentration (similar to that after subcutaneous rapid-acting insulins and faster than that after subcutaneous <a class="drug drug_general" data-topicid="9030" href="/d/drug information/9030.html" rel="external">regular insulin</a>). It is designed to be used to manage postprandial glucose levels. Inhaled insulin may cause a transient cough with each inhalation, and it requires pulmonary monitoring. It is used infrequently in patients with type 2 diabetes. (See  <a class="medical medical_review" href="/d/html/1764.html" rel="external">"Inhaled insulin therapy in diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colesevelam</strong> – <a class="drug drug_general" data-topicid="8954" href="/d/drug information/8954.html" rel="external">Colesevelam</a> is a bile acid sequestrant that lowers low-density lipoprotein (LDL) cholesterol in patients with primary hypercholesterolemia (see  <a class="medical medical_review" href="/d/html/4562.html" rel="external">"Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors", section on 'Bile acid sequestrants'</a>). Colesevelam's mechanism of action to improve glycemia is uncertain [<a href="#rid64">64</a>]. One possibility is that bile acid sequestrants act in the GI tract to reduce glucose absorption.</p><p></p><p class="bulletIndent1">In a meta-analysis of five short-term trials (16 to 26 weeks) in patients with type 2 diabetes inadequately treated with oral agents or insulin, the addition of <a class="drug drug_general" data-topicid="8954" href="/d/drug information/8954.html" rel="external">colesevelam</a> compared with placebo modestly reduced A1C levels (mean difference 0.5 percentage points, 95% CI -0.6 to -0.4) [<a href="#rid65">65</a>]. The meta-analysis was limited by the high or unclear risk of bias in the individual trials.</p><p></p><p class="bulletIndent1">Side effects can include constipation, nausea, and dyspepsia. In contrast to its effects on LDL cholesterol, <a class="drug drug_general" data-topicid="8954" href="/d/drug information/8954.html" rel="external">colesevelam</a> increases triglyceride concentrations by approximately 20 percent [<a href="#rid66">66,67</a>]. The clinical implications of this increase are unknown. (See  <a class="medical medical_review" href="/d/html/4565.html" rel="external">"Lipoprotein classification, metabolism, and role in atherosclerosis", section on 'Apolipoprotein C-III'</a>.)</p><p></p><p class="bulletIndent1">Given the modest glucose-lowering effectiveness, expense, and limited clinical experience, we typically do not recommend <a class="drug drug_general" data-topicid="8954" href="/d/drug information/8954.html" rel="external">colesevelam</a> to improve glycemic management in patients with type 2 diabetes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bromocriptine</strong> – <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">Bromocriptine</a> is an ergot-derived dopamine agonist that has been used for over two decades for the treatment of hyperprolactinemia and Parkinson disease. (See  <a class="medical medical_review" href="/d/html/6630.html" rel="external">"Management of hyperprolactinemia", section on 'Overview of dopamine agonists'</a>.)</p><p></p><p class="bulletIndent1">A quick-release formulation of <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> has been approved by the FDA for the treatment of type 2 diabetes mellitus [<a href="#rid68">68</a>]. In short-term clinical trials in patients with type 2 diabetes mellitus, bromocriptine (up to 4.8 mg daily) as monotherapy or as adjunctive therapy to sulfonylureas was minimally effective in reducing A1C compared with placebo (mean difference 0.4 to 0.5 percentage points) [<a href="#rid68">68,69</a>]. Common side effects include nausea, vomiting, dizziness, and headache [<a href="#rid70">70</a>]. The mechanism of action in reducing blood sugar is unknown.</p><p></p><p class="bulletIndent1">Given its modest glucose-lowering effect, very frequent GI side effects, and the availability of more effective drugs, we do not recommend <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a> for the treatment of type 2 diabetes.</p><p></p><p class="headingAnchor" id="H1665282"><span class="h1">BARIATRIC (METABOLIC) SURGERY</span><span class="headingEndMark"> — </span>In patients with type 2 diabetes and obesity, bariatric and metabolic surgical procedures that result in sustained, major weight loss have been shown to lead to at least temporary remission of diabetes in a substantial fraction of patients. Bariatric surgical procedures are targeted at weight loss in the setting of obesity; the term "metabolic surgery" is used when a major goal of surgery is to improve diabetes or other metabolic diseases (eg, nonalcoholic fatty liver disease).</p><p class="headingAnchor" id="H2093658710"><span class="h2">Patient selection</span><span class="headingEndMark"> — </span>Surgical treatment of obesity is an option to treat type 2 diabetes in appropriate surgical candidates with [<a href="#rid71">71</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Body mass index (BMI) ≥40 kg/m<sup>2</sup> (BMI ≥37.5 kg/m<sup>2</sup> in Asian Americans)</p><p class="bulletIndent1"><span class="glyph">●</span>BMI 35 to 39.9 kg/m<sup>2</sup> (BMI 32.5 to 37.4 kg/m<sup>2</sup> in Asian Americans) when hyperglycemia is inadequately managed by lifestyle measures and optimal medical therapy</p><p></p><p>Surgical treatment has also been endorsed in patients with type 2 diabetes with BMI 30 to 34.9 kg/m<sup>2</sup> (or ≥27.5 kg/m<sup>2</sup> in Asian American individuals) if hyperglycemia has been inadequately managed despite optimal treatment with medications, especially if other obesity-related comorbidities are present, and is now recommended by the ADA [<a href="#rid72">72</a>]. Given the increasing availability of potent GLP-1-based therapies and lack of comparative effectiveness data for bariatric surgery and these potent agents, we review these options with our patients and engage in shared decision-making. (See  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Diabetes education'</a> and  <a class="medical medical_review" href="/d/html/586.html" rel="external">"Bariatric surgery for management of obesity: Indications and preoperative preparation", section on 'Indications'</a>.)</p><p class="headingAnchor" id="H616558643"><span class="h2">Outcomes</span><span class="headingEndMark"> — </span>Unblinded trials have compared bariatric surgery with medical therapy for the treatment of type 2 diabetes (see  <a class="medical medical_review" href="/d/html/90469.html" rel="external">"Outcomes of bariatric surgery", section on 'Diabetes mellitus'</a>). In a meta-analysis of trials comparing bariatric surgery with medical/lifestyle treatments for type 2 diabetes, surgery reduced body weight and improved glycemia more effectively than medical/lifestyle interventions (median A1C reduction 2 versus 0.5 percentage points for conventional therapy) [<a href="#rid71">71</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diabetes remission</strong> – An international group of experts convened by the American Diabetes Association (ADA) defines diabetes remission as an A1C &lt;6.5 percent sustained for at least three months following discontinuation of any glucose-lowering medications [<a href="#rid73">73</a>]. In a prospective observational study of 316 patients with type 2 diabetes who previously participated in a trial of surgery versus medical/lifestyle therapy, diabetes remission (A1C ≤6.5 percent for three months without medication) at three years was achieved in 37.5 and 2.6 percent of patients, respectively [<a href="#rid74">74</a>]. However, relapse of diabetes usually occurs over time, with 35 to 50 percent of patients who initially achieved diabetes remission after surgery experiencing a recurrence [<a href="#rid72">72,75</a>]. Nevertheless, bariatric surgery improves glycemia substantially and significantly more than medication therapy, and most patients have marked improvement in glycemic management for at least 5 to 15 years after surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diabetes-related complications</strong> – Although observational data suggest improvement in micro- and macrovascular outcomes [<a href="#rid76">76-79</a>], there are no long-term, high-quality studies (randomized trials) of micro- and macrovascular complications. The effects of bariatric surgery on diabetes-related complications are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/90469.html" rel="external">"Outcomes of bariatric surgery", section on 'Diabetic complications'</a>.)</p><p></p><p class="headingAnchor" id="H3566044957"><span class="h2">Risks and concerns</span><span class="headingEndMark"> — </span>Despite these impressive metabolic results, concerns remain about acute postoperative complications including the need for reoperations and rehospitalizations and rare, but potentially severe, adverse events; the long-term success rates in maintaining weight loss [<a href="#rid71">71,80,81</a>]; and the reproducibility of the results in patients with an extensive history of diabetes or with different surgical teams [<a href="#rid82">82</a>]. Some weight regain is typical within two to three years of bariatric procedures, and different procedures result in different levels of weight loss and corresponding reductions in glycemia. Bariatric surgical procedures are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/88536.html" rel="external">"Bariatric procedures for the management of severe obesity: Descriptions"</a> and  <a class="medical medical_review" href="/d/html/586.html" rel="external">"Bariatric surgery for management of obesity: Indications and preoperative preparation"</a> and  <a class="medical medical_review" href="/d/html/87686.html" rel="external">"Bariatric operations: Early (fewer than 30 days) morbidity and mortality"</a>.)</p><p class="headingAnchor" id="H2595809638"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104442.html" rel="external">"Society guideline links: Diabetes mellitus in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/111575.html" rel="external">"Society guideline links: Diabetes mellitus in children"</a> and  <a class="medical medical_society_guidelines" href="/d/html/140971.html" rel="external">"Society guideline links: Diabetic kidney disease"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15402.html" rel="external">"Patient education: Type 2 diabetes (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15595.html" rel="external">"Patient education: Treatment for type 2 diabetes (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1743.html" rel="external">"Patient education: Type 2 diabetes: Overview (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1737.html" rel="external">"Patient education: Type 2 diabetes: Treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1744.html" rel="external">"Patient education: Glucose monitoring in diabetes (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1741.html" rel="external">"Patient education: Preventing complications from diabetes (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indication for a second agent</strong> – For most patients, we recommend a second medication when the individualized glycemic treatment goal is not achieved with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> plus lifestyle intervention (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). This decision is based on glycated hemoglobin (A1C) assay results (<a class="calc calc_professional" href="/d/html/15628.html" rel="external">calculator 1</a>) typically performed every three to six months after initial therapy. After a successful initial response to lifestyle intervention and oral therapy, the majority of patients do not maintain target A1C levels during the subsequent three to five years. (See <a class="local">'Indications for a second agent'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><strong>Monotherapy failure</strong> – For patients who do not achieve their goal glycemia on initial oral therapy, many medication classes are available that can be used with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>. Options include glucagon-like peptide 1 (GLP-1) receptor agonists, a dual-acting GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (<a class="drug drug_general" data-topicid="138675" href="/d/drug information/138675.html" rel="external">tirzepatide</a>), sodium-glucose co-transporter 2 (SGLT2) inhibitors, short-acting sulfonylureas (eg, <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a>, <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a>), <a class="drug drug_general" data-topicid="9604" href="/d/drug information/9604.html" rel="external">repaglinide</a> (if sulfonylurea not chosen as initial therapy), insulin, dipeptidyl peptidase 4 (DPP-4) inhibitors, and <a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">pioglitazone</a>  (<a class="graphic graphic_figure graphicRef111617" href="/d/graphic/111617.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef56876" href="/d/graphic/56876.html" rel="external">table 2</a>). For patients with persistent hyperglycemia while taking a maximally tolerated dose of metformin, the choice of a second medication should be individualized based on efficacy, risk for hypoglycemia, the patient's comorbid conditions, impact on weight, side effects, and cost. (See <a class="local">'Monotherapy failure'</a> above.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-129531">(Related Pathway(s):  <a class="utd-content-129531" href="/pathway/129531?topicRef=1790&amp;source=see_link">Diabetes: Medication selection for non-pregnant adults with type 2 DM and persistent hyperglycemia despite monotherapy</a>.)</span></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>A1C &gt;9 percent</strong> – For patients with A1C &gt;9 percent (74.9 mmol/mol), we suggest adding insulin, a GLP-1 receptor agonist, or a dual-acting GLP-1 and GIP receptor agonist (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). These agents have been shown to have the best glycemic efficacy  (<a class="graphic graphic_algorithm graphicRef135209" data-inline-graphics="135209" href="/d/graphic/135209.html" rel="external">algorithm 1</a>). (See <a class="local">'A1C &gt;9 percent (74.9 mmol/mol) or persistent symptoms of hyperglycemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Catabolic symptoms</strong> – Insulin is always effective and is preferred in catabolic diabetes (eg, polyuria, polydipsia, weight loss) or when distinguishing between type 1 and type 2 diabetes is difficult. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Existing cardiovascular disease or high atherosclerotic cardiovascular disease (ASCVD) risk</strong> – For patients with established ASCVD or high ASCVD risk, specific GLP-1 receptor agonists that have demonstrated cardiovascular benefit (<a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a>, subcutaneous <a class="drug drug_general" data-topicid="115980" href="/d/drug information/115980.html" rel="external">semaglutide</a>, or <a class="drug drug_general" data-topicid="97148" href="/d/drug information/97148.html" rel="external">dulaglutide</a>) are preferred, assuming that they achieve the desired glycemic target. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Without catabolic symptoms or ASCVD disease</strong> – For patients without either catabolic symptoms or existing cardiac disease, a GLP-1 receptor agonist or dual-acting GLP-1 and GIP receptor agonist may be favored when weight loss is important. Gastrointestinal (GI) side effects, contraindications, and cost may limit their use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>A1C ≤9 percent</strong> – For patients with A1C ≤9 percent, the choice of a second medication should be individualized primarily based upon the presence of cardiovascular or kidney comorbidities  (<a class="graphic graphic_algorithm graphicRef135210" href="/d/graphic/135210.html" rel="external">algorithm 2</a>). (See <a class="local">'Without established cardiovascular or kidney disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiovascular and/or kidney comorbidities</strong> – For patients with existing cardiovascular and kidney comorbidities who have persistent hyperglycemia while taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, we recommend adding a GLP-1 receptor agonist (<a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a>, subcutaneous <a class="drug drug_general" data-topicid="115980" href="/d/drug information/115980.html" rel="external">semaglutide</a>, or <a class="drug drug_general" data-topicid="97148" href="/d/drug information/97148.html" rel="external">dulaglutide</a>) or an SGLT2 inhibitor (<a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a>) that has demonstrated cardiovascular and kidney benefit (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). To select a medication, we use shared decision-making with a focus on beneficial and adverse effects within the context of the degree of hyperglycemia as well as a patient's comorbidities and preferences  (<a class="graphic graphic_algorithm graphicRef135210" href="/d/graphic/135210.html" rel="external">algorithm 2</a>). (See <a class="local">'Established cardiovascular or kidney disease'</a> above.) </p><p></p><p class="bulletIndent2">The majority of patients in the cardiovascular and renal outcomes trials had established cardiovascular disease (CVD) or diabetic kidney disease (DKD) with severely increased albuminuria, and therefore, these are the primary indications for one of these drugs. Patients at high CVD risk but without a prior event might benefit, but the data are less supportive. Similarly, patients without severely increased albuminuria have some benefit, but the absolute benefits are greater among those with severely increased albuminuria.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Absence of ASCVD, heart failure (HF), or DKD</strong> – For patients without established cardiovascular or kidney disease who have persistent hyperglycemia while taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, we suggest a GLP-1 receptor agonist or basal insulin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients who are opposed to injection therapy and/or who decline or cannot tolerate GLP-1 receptor agonists or insulin, other available medications also effectively reduce A1C. The choice of an alternative glucose-lowering medication is guided by efficacy, patient comorbidities, preferences, side effects, and cost.  (<a class="graphic graphic_algorithm graphicRef135210" href="/d/graphic/135210.html" rel="external">algorithm 2</a>). (See <a class="local">'Without established cardiovascular or kidney disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dual agent failure</strong> – For patients with inadequate glycemic management on dual therapy, the choice of additional therapy should be individualized similarly as for patients with monotherapy failure based upon efficacy, risk of hypoglycemia, the patient's underlying comorbidities, impact on weight, side effects, and cost. (See <a class="local">'Dual agent failure'</a> above.)</p><p></p><p class="bulletIndent1">For most patients who do not achieve target A1C with initial dual therapy, we suggest starting insulin or a GLP-1 receptor agonist (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>) (if neither already chosen as a second agent). In patients on sulfonylureas and <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> who are starting insulin therapy, sulfonylureas are generally tapered and discontinued, while metformin is continued. In patients on DPP-4 inhibitors who are starting a GLP-1 receptor agonist or dual-acting GLP-1 and GIP receptor agonist, the DPP-4 inhibitor is discontinued, while metformin is continued. (See <a class="local">'Dual agent failure'</a> above and <a class="local">'Insulin initiation and intensification'</a> above.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120430">(Related Pathway(s):  <a class="utd-content-120430" href="/pathway/120430?topicRef=1790&amp;source=see_link">Diabetes: Initial therapy for non-pregnant adults with type 2 DM</a>.)</span></p><p></p><p class="bulletIndent1">An alternative is two oral agents and a GLP-1 receptor agonist or dual-acting GLP-1 and GIP receptor agonist, particularly for patients in whom weight loss or avoidance of hypoglycemia is a primary consideration. These GLP-1-based therapies should not be combined with DPP-4 inhibitors. Another option for patients close to glycemic goals is three oral agents (eg, <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, sulfonylurea plus: DPP-4 inhibitor, SGLT2 inhibitor, or <a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">pioglitazone</a>). Although guidelines suggest combining SGLT2 inhibitors and GLP-1 receptor agonists, we do not usually add an SGLT2 inhibitor to GLP-1 receptor agonist therapy for management of hyperglycemia alone, given the absence of data showing additive cardiovascular and kidney benefit and increased patient burden (cost, polypharmacy, adverse effects). However, we do combine the medications if strong indications exist for each class (eg, a patient with type 2 diabetes, obesity, A1C &gt;9 percent, and severely elevated albuminuria).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity class II or III</strong> – For selected patients with type 2 diabetes and obesity (appropriate surgical candidates with body mass index [BMI] ≥40 kg/m<sup>2</sup> or BMI 35 to 39.9 kg/m<sup>2</sup> when hyperglycemia is inadequately managed by lifestyle measures and optimal medical therapy), we suggest bariatric surgery (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Bariatric surgery may also be an option in patients with lower BMI (30 to 34.9 kg/m<sup>2</sup>) when hyperglycemia is inadequately managed by optimal medical therapy, especially when other obesity-related comorbidities are present. Patients seeking bariatric surgery should be counseled to develop coping skills, eliminate maladaptive behavior, and understand the risks and benefits of the surgery. (See <a class="local">'Bariatric (metabolic) surgery'</a> above and  <a class="medical medical_review" href="/d/html/586.html" rel="external">"Bariatric surgery for management of obesity: Indications and preoperative preparation", section on 'Preoperative counseling'</a>.)</p><p></p><p class="headingAnchor" id="H4155848271"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David McCulloch, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S158.</a></li><li><a class="nounderline abstract_t">Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022; 65:1925.</a></li><li><a class="nounderline abstract_t">Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care 2012; 35:2650.</a></li><li><a class="nounderline abstract_t">Wei N, Zheng H, Nathan DM. Empirically establishing blood glucose targets to achieve HbA1c goals. Diabetes Care 2014; 37:1048.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S111.</a></li><li><a class="nounderline abstract_t">Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.</a></li><li><a class="nounderline abstract_t">United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310:83.</a></li><li><a class="nounderline abstract_t">U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44:1249.</a></li><li><a class="nounderline abstract_t">Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281:2005.</a></li><li><a class="nounderline abstract_t">GRADE Study Research Group, Nathan DM, Lachin JM, et al. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med 2022; 387:1063.</a></li><li><a class="nounderline abstract_t">Bressler P, DeFronzo RA. Drugs and diabetes. Diabetes Reviews 1994; 2:53.</a></li><li><a class="nounderline abstract_t">Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27:1535.</a></li><li><a class="nounderline abstract_t">Shah BR, Hux JE, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005; 28:600.</a></li><li><a class="nounderline abstract_t">Ziemer DC, Doyle JP, Barnes CS, et al. An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes (IPCAAD) 8. Arch Intern Med 2006; 166:507.</a></li><li><a class="nounderline abstract_t">Grant RW, Buse JB, Meigs JB, University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care 2005; 28:337.</a></li><li><a class="nounderline abstract_t">Fanning EL, Selwyn BJ, Larme AC, DeFronzo RA. Improving efficacy of diabetes management using treatment algorithms in a mainly Hispanic population. Diabetes Care 2004; 27:1638.</a></li><li><a class="nounderline abstract_t">Grant RW, Cagliero E, Sullivan CM, et al. A controlled trial of population management: diabetes mellitus: putting evidence into practice (DM-PEP). Diabetes Care 2004; 27:2299.</a></li><li><a class="nounderline abstract_t">Das SR, Everett BM, Birtcher KK, et al. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2018; 72:3200.</a></li><li class="breakAll">http://www.who.int/diabetes/publications/guidelines-diabetes-medicines/en/ (Accessed on September 07, 2018).</li><li><a class="nounderline abstract_t">Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Ann Intern Med 2020; 173:278.</a></li><li><a class="nounderline abstract_t">Maruthur NM, Tseng E, Hutfless S, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164:740.</a></li><li><a class="nounderline abstract_t">Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. JAMA 2016; 316:313.</a></li><li><a class="nounderline abstract_t">Rodbard HW, Rosenstock J, Canani LH, et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care 2019; 42:2272.</a></li><li><a class="nounderline abstract_t">Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol 2019; 7:834.</a></li><li><a class="nounderline abstract_t">Henry RR, Gumbiner B, Ditzler T, et al. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993; 16:21.</a></li><li><a class="nounderline abstract_t">Hemmingsen B, Christensen LL, Wetterslev J, et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ 2012; 344:e1771.</a></li><li><a class="nounderline abstract_t">Yki-Järvinen H, Ryysy L, Nikkilä K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999; 130:389.</a></li><li><a class="nounderline abstract_t">Wulffelé MG, Kooy A, Lehert P, et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002; 25:2133.</a></li><li><a class="nounderline abstract_t">Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009; 169:616.</a></li><li><a class="nounderline abstract_t">Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854.</a></li><li><a class="nounderline abstract_t">Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52:2046.</a></li><li><a class="nounderline abstract_t">Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375:2234.</a></li><li><a class="nounderline abstract_t">Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; :CD006423.</a></li><li><a class="nounderline abstract_t">Singh S, Wright EE Jr, Kwan AY, et al. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 2017; 19:228.</a></li><li><a class="nounderline abstract_t">Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021; 385:503.</a></li><li><a class="nounderline abstract_t">Curovic VR, Jongs N, Kroonen MYAM, et al. Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial. Diabetes Care 2023; 46:593.</a></li><li><a class="nounderline abstract_t">Shields BM, Dennis JM, Angwin CD, et al. Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study. Nat Med 2023; 29:376.</a></li><li><a class="nounderline abstract_t">Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA 2018; 319:1580.</a></li><li><a class="nounderline abstract_t">Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2023; 381:e074068.</a></li><li><a class="nounderline abstract_t">Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375:1834.</a></li><li><a class="nounderline abstract_t">Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375:311.</a></li><li><a class="nounderline abstract_t">Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377:839.</a></li><li><a class="nounderline abstract_t">Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394:121.</a></li><li><a class="nounderline abstract_t">Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 2019; 394:131.</a></li><li><a class="nounderline abstract_t">Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021; 372:m4573.</a></li><li><a class="nounderline abstract_t">Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev 2021; 10:CD013650.</a></li><li><a class="nounderline abstract_t">Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380:2295.</a></li><li><a class="nounderline abstract_t">Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383:1436.</a></li><li><a class="nounderline abstract_t">Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380:347.</a></li><li><a class="nounderline abstract_t">Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373:2117.</a></li><li><a class="nounderline abstract_t">Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377:644.</a></li><li><a class="nounderline abstract_t">Patorno E, Htoo PT, Glynn RJ, et al. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med 2021; 174:1528.</a></li><li><a class="nounderline abstract_t">Colling C, Atlas SJ, Wexler DJ. Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care. Diabetes Care 2021; 44:1443.</a></li><li><a class="nounderline abstract_t">GRADE Study Research Group, Nathan DM, Lachin JM, et al. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med 2022; 387:1075.</a></li><li><a class="nounderline abstract_t">Wexler DJ, de Boer IH, Ghosh A, et al. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial. JAMA Intern Med 2023; 183:705.</a></li><li><a class="nounderline abstract_t">Hirst JA, Farmer AJ, Dyar A, et al. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013; 56:973.</a></li><li><a class="nounderline abstract_t">Nauck MA, Kahle M, Baranov O, et al. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab 2017; 19:200.</a></li><li><a class="nounderline abstract_t">Zaccardi F, Dhalwani NN, Dales J, et al. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. Diabetes Obes Metab 2018; 20:985.</a></li><li><a class="nounderline abstract_t">Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41:2669.</a></li><li><a class="nounderline abstract_t">Das SR, Everett BM, Birtcher KK, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020; 76:1117.</a></li><li><a class="nounderline abstract_t">Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193.</a></li><li><a class="nounderline abstract_t">Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121:928.</a></li><li><a class="nounderline abstract_t">Johnston PS, Feig PU, Coniff RF, et al. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care 1998; 21:409.</a></li><li><a class="nounderline abstract_t">In Brief: A new indication for colesevelam. Med Lett Drugs Ther 2008; 50:33.</a></li><li><a class="nounderline abstract_t">Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev 2012; 12:CD009361.</a></li><li><a class="nounderline abstract_t">Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008; 31:1479.</a></li><li><a class="nounderline abstract_t">Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008; 168:1531.</a></li><li><a class="nounderline abstract_t">Bromocriptine (Cycloset) for type 2 diabetes. Med Lett Drugs Ther 2010; 52:97.</a></li><li><a class="nounderline abstract_t">Cincotta AH, Meier AH, Cincotta Jr  M. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999; 8:1683.</a></li><li><a class="nounderline abstract_t">Gaziano JM, Cincotta AH, O'Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010; 33:1503.</a></li><li><a class="nounderline abstract_t">Rubino F, Nathan DM, Eckel RH, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care 2016; 39:861.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S145.</a></li><li><a class="nounderline abstract_t">Riddle MC, Cefalu WT, Evans PH, et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care 2021; 44:2438.</a></li><li><a class="nounderline abstract_t">Kirwan JP, Courcoulas AP, Cummings DE, et al. Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). Diabetes Care 2022; 45:1574.</a></li><li><a class="nounderline abstract_t">Ikramuddin S, Korner J, Lee WJ, et al. Durability of Addition of Roux-en-Y Gastric Bypass to Lifestyle Intervention and Medical Management in Achieving Primary Treatment Goals for Uncontrolled Type 2 Diabetes in Mild to Moderate Obesity: A Randomized Control Trial. Diabetes Care 2016; 39:1510.</a></li><li><a class="nounderline abstract_t">Fisher DP, Johnson E, Haneuse S, et al. Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity. JAMA 2018; 320:1570.</a></li><li><a class="nounderline abstract_t">O'Brien R, Johnson E, Haneuse S, et al. Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study. Ann Intern Med 2018; 169:300.</a></li><li><a class="nounderline abstract_t">Carlsson LMS, Sjöholm K, Karlsson C, et al. Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol 2017; 5:271.</a></li><li><a class="nounderline abstract_t">Reynolds EL, Watanabe M, Banerjee M, et al. The effect of surgical weight loss on diabetes complications in individuals with class II/III obesity. Diabetologia 2023; 66:1192.</a></li><li><a class="nounderline abstract_t">Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2015; 386:964.</a></li><li><a class="nounderline abstract_t">Courcoulas AP, Belle SH, Neiberg RH, et al. Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial. JAMA Surg 2015; 150:931.</a></li><li><a class="nounderline abstract_t">Ludwig DS, Ebbeling CB, Livingston EH. Surgical vs lifestyle treatment for type 2 diabetes. JAMA 2012; 308:981.</a></li></ol></div><div id="topicVersionRevision">Topic 1790 Version 96.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078590" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36151309" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23100048" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diabetes in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24513588" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Empirically establishing blood glucose targets to achieve HbA1c goals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078586" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9742976" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7833731" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7589820" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10359389" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36129996" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Drugs and diabetes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220224" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The burden of treatment failure in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15735195" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534036" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes (IPCAAD) 8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15677789" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220240" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Improving efficacy of diabetes management using treatment algorithms in a mainly Hispanic population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15451891" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A controlled trial of population management: diabetes mellitus: putting evidence into practice (DM-PEP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30497881" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30497881" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32598218" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27088241" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27434443" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31530666" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31540867" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8422777" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22517929" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10068412" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12453950" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Combination of insulin and metformin in the treatment of type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19307526" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9742977" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19688338" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20609969" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21975753" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Glucagon-like peptide analogues for type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27717130" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34170647" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36657986" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36477733" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29677303" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37024129" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27633186" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27295427" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28854085" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Liraglutide and Renal Outcomes in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31189511" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31189509" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33441402" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34693515" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30990260" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32970396" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Dapagliflozin in Patients with Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415602" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26378978" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28605608" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34570599" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34016618" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36129997" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37213109" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23494446" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27709794" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29205774" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30291106" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32771263" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18945920" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7734015" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9540024" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : In Brief: A new indication for colesevelam</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235674" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Colesevelam for type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18458145" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18663165" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21344781" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Bromocriptine (Cycloset) for type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11139820" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20332352" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27222544" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078578" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34462270" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35320365" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27311493" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Durability of Addition of Roux-en-Y Gastric Bypass to Lifestyle Intervention and Medical Management in Achieving Primary Treatment Goals for Uncontrolled Type 2 Diabetes in Mild to Moderate Obesity: A Randomized Control Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30326126" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30083761" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28237791" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36917280" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The effect of surgical weight loss on diabetes complications in individuals with class II/III obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26369473" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26132586" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22968885" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Surgical vs lifestyle treatment for type 2 diabetes.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
